EGFR and dermatological toxicity: Treatment with drugs inhibiting the epidermal growth factor receptor (EGFR) often causes skin toxicities within the first weeks of treatment.1 These skin reactions can lead to physical and psychosocial discomfort affecting treatment adherence and clinical outcome.2 Special skin care and tetracyclines are used as prophylactic treatment,3 but still a high percentage (20%‐30%) of patients treated with drugs targeting EGFR suffer from NCI‐CTC ≥ grade 2 skin toxicities.2, 4